Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


JP Morgan Notebook Day One: Pfizer/Allergan, Celgene, Gilead, Teva And More

This article was originally published in Scrip

Executive Summary

Pfizer Inc. chairman and CEO Ian Read and Allergan PLC president and CEO Brent Saunders noted in a Jan. 11 interview with Scrip during the 34th Annual JP Morgan Healthcare Conference in San Francisco that investors' biggest concern about the pending $160bn merger of the two companies do not revolve around whether or not the combined entity will continue early-stage research and development or whether more dealmaking is on the horizon.


Related Content

Roivant's Ramaswamy Woos Celgene's Fouse To Lead Dermavant





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts